MG0003 A Phase 3 Randomized Double-Blind Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients with Generalized Myasthenia Gravis
Brief description of study
This is a Phase 3 study of rozanolixizumab in anti-AChR or
anti-MuSK autoantibody-positive patients with generalized MG who
experience moderate to severe symptoms and are being considered for
treatment with IVIg or PEX. The primary objective of the study is to
demonstrate the clinical efficacy of rozanolixizumab in patients with
generalized Myasthenia Gravis.
All
participants will be consented and enrolled by the Penn PI or Sub-I. Referrals
will be accepted but we plan to recruit patients from within Penn Medicine clinics.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
myasthenia gravis
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
10 Jun 2021.
Study ID: 833604
